Skip to main content
Top
Published in: Diabetes Therapy 6/2017

Open Access 01-12-2017 | Original Research

A Randomized Controlled Trial to Assess the Impact of Proper Insulin Injection Technique Training on Glycemic Control

Authors: Inna V. Misnikova, Valeria A. Gubkina, Tatyana S. Lakeeva, Alexander V. Dreval

Published in: Diabetes Therapy | Issue 6/2017

Login to get access

Abstract

Introduction

Improper injection technique can negatively affect glycemic control and treatment tolerability. We assessed the impact of structured insulin injection training on glycemic control.

Methods

We compared changes in glycated hemoglobin (A1C) and fasting plasma glucose following structured insulin injection training in a 6-month pilot study in patients with type 1 or 2 diabetes. Patients were recruited from mobile clinics in Moscow, Russia, and randomized into three groups. Groups 1 and 2 received structured injection training, and group 3 did not. Group 1 received 4-mm needles sufficient for each injection; groups 2 and 3 provided their own needle supply. Changes in insulin total daily dose (TDD), injection technique, needle reuse, and lipohypertrophy (LH) were assessed.

Results

Of 120 patients enrolled, 116 were included in all analyses (group 1, n = 43; group 2, n = 35; group 3, n = 38). At 6 months, mean [95% CI] reductions in A1C were significant in groups 1 and 2 (− 1.00% [10.9 mmol/mol (− 1.3 to − 0.6)] and − 1.00% [10.9 mmol/mol (− 1.4 to − 0.7)], respectively; P < 0.001 for both), but not in group 3 (− 0.02% [0.2 mmol/mol (− 1.2 to 1.6)]). Increases in insulin TDD, however, were similar and significant across groups (approximately 6 IU; P < 0.05). Injection technique improved, and needle reuse and LH declined in groups 1 and 2, but not in group 3.

Conclusions

Little is known about the glycemic impact of insulin injection training. We found that structured training and the use of short pen needles can improve injection technique, leading to significant A1C reductions and decreased rates of LH.
Appendix
Available only for authorised users
Literature
1.
go back to reference International Diabetes Federation Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels: Int Diabetes Federation; 2012. International Diabetes Federation Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels: Int Diabetes Federation; 2012.
2.
go back to reference Gururaj Setty S, Crasto W, Jarvis J, Khunti K, Davies MJ. New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. Postgrad Med J. 2016;92:152–64.CrossRefPubMed Gururaj Setty S, Crasto W, Jarvis J, Khunti K, Davies MJ. New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. Postgrad Med J. 2016;92:152–64.CrossRefPubMed
3.
go back to reference Kostev K, Dippel FW, Rathmann W. Glycemic control after initiating basal insulin therapy in patients with type 2 diabetes: a primary care database analysis. Diabetes Metab Syndr Obes. 2015;8:45–8.CrossRefPubMedPubMedCentral Kostev K, Dippel FW, Rathmann W. Glycemic control after initiating basal insulin therapy in patients with type 2 diabetes: a primary care database analysis. Diabetes Metab Syndr Obes. 2015;8:45–8.CrossRefPubMedPubMedCentral
4.
go back to reference American Diabetes Association. Professional Practice Committee for the Standards of Medical Care in Diabetes 2016. Diabetes Care. 2016;39:S107–8.CrossRef American Diabetes Association. Professional Practice Committee for the Standards of Medical Care in Diabetes 2016. Diabetes Care. 2016;39:S107–8.CrossRef
5.
go back to reference Pimouguet C, Le Goff M, Thiebaut R, Dartigues JF, Helmer C. Effectiveness of disease-management programs for improving diabetes care: a meta-analysis. CMAJ. 2011;183:E115–27.CrossRefPubMedPubMedCentral Pimouguet C, Le Goff M, Thiebaut R, Dartigues JF, Helmer C. Effectiveness of disease-management programs for improving diabetes care: a meta-analysis. CMAJ. 2011;183:E115–27.CrossRefPubMedPubMedCentral
6.
go back to reference Norris SL, Lau J, Smith SJ, Schmid CH, Engelgau MM. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. Diabetes Care. 2002;25:1159–71.CrossRefPubMed Norris SL, Lau J, Smith SJ, Schmid CH, Engelgau MM. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. Diabetes Care. 2002;25:1159–71.CrossRefPubMed
9.
go back to reference Frid AH, Kreugel G, Grassi G, et al. New insulin delivery recommendations. Mayo Clin Proc. 2016;91:1231–55.CrossRefPubMed Frid AH, Kreugel G, Grassi G, et al. New insulin delivery recommendations. Mayo Clin Proc. 2016;91:1231–55.CrossRefPubMed
10.
go back to reference Grassi G, Scuntero P, Trepiccioni R, Marubbi F, Strauss K. Optimizing insulin injection technique and its effect on blood glucose control. J Clin Trans Endocrinol. 2014;1:145–50. Grassi G, Scuntero P, Trepiccioni R, Marubbi F, Strauss K. Optimizing insulin injection technique and its effect on blood glucose control. J Clin Trans Endocrinol. 2014;1:145–50.
11.
go back to reference Frid AH, Hirsch LJ, Menchior AR, Morel DR, Strauss KW. Worldwide Injection Technique Questionnaire Study: injecting complications and the role of the professional. Mayo Clin Proc. 2016;91:1224–30.CrossRefPubMed Frid AH, Hirsch LJ, Menchior AR, Morel DR, Strauss KW. Worldwide Injection Technique Questionnaire Study: injecting complications and the role of the professional. Mayo Clin Proc. 2016;91:1224–30.CrossRefPubMed
12.
go back to reference Spollett G, Edelman SV, Mehner P, Walter C, Penfornis A. Improvement of insulin injection technique: examination of current issues and recommendations. Diabetes Educ. 2016;42:379–94.CrossRefPubMed Spollett G, Edelman SV, Mehner P, Walter C, Penfornis A. Improvement of insulin injection technique: examination of current issues and recommendations. Diabetes Educ. 2016;42:379–94.CrossRefPubMed
13.
go back to reference Blanco M, Hernandez MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013;39:445–53.CrossRefPubMed Blanco M, Hernandez MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013;39:445–53.CrossRefPubMed
14.
go back to reference Ji J, Lou Q. Insulin pen injection technique survey in patients with type 2 diabetes in mainland China in 2010. Curr Med Res Opin. 2014;30:1087–93.CrossRefPubMed Ji J, Lou Q. Insulin pen injection technique survey in patients with type 2 diabetes in mainland China in 2010. Curr Med Res Opin. 2014;30:1087–93.CrossRefPubMed
15.
go back to reference Frid AH, Hirsch LJ, Menchior AR, Morel DR, Strauss KW. Worldwide injection technique questionnaire study: population parameters and injection practices. Mayo Clin Proc. 2016;91:1212–23.CrossRefPubMed Frid AH, Hirsch LJ, Menchior AR, Morel DR, Strauss KW. Worldwide injection technique questionnaire study: population parameters and injection practices. Mayo Clin Proc. 2016;91:1212–23.CrossRefPubMed
16.
go back to reference Vardar B, Kizilci S. Incidence of lipohypertrophy in diabetic patients and a study of influencing factors. Diabetes Res Clin Pract. 2007;77:231–6.CrossRefPubMed Vardar B, Kizilci S. Incidence of lipohypertrophy in diabetic patients and a study of influencing factors. Diabetes Res Clin Pract. 2007;77:231–6.CrossRefPubMed
17.
go back to reference Johansson UB, Amsberg S, Hannerz L, et al. Impaired absorption of insulin aspart from lipohypertrophic injection sites. Diabetes Care. 2005;28:2025–7.CrossRefPubMed Johansson UB, Amsberg S, Hannerz L, et al. Impaired absorption of insulin aspart from lipohypertrophic injection sites. Diabetes Care. 2005;28:2025–7.CrossRefPubMed
18.
go back to reference Famulla S, Hovelmann U, Fischer A, et al. Insulin injection into lipohypertrophic tissue: blunted and more variable insulin absorption and action and impaired postprandial glucose control. Diabetes Care. 2016;39:1486–92.CrossRefPubMed Famulla S, Hovelmann U, Fischer A, et al. Insulin injection into lipohypertrophic tissue: blunted and more variable insulin absorption and action and impaired postprandial glucose control. Diabetes Care. 2016;39:1486–92.CrossRefPubMed
19.
go back to reference Hirsch L, Byron K, Gibney M. Intramuscular risk at insulin injection sites–measurement of the distance from skin to muscle and rationale for shorter-length needles for subcutaneous insulin therapy. Diabetes Technol Ther. 2014;16:867–73.CrossRefPubMed Hirsch L, Byron K, Gibney M. Intramuscular risk at insulin injection sites–measurement of the distance from skin to muscle and rationale for shorter-length needles for subcutaneous insulin therapy. Diabetes Technol Ther. 2014;16:867–73.CrossRefPubMed
20.
go back to reference Bergenstal RM, Strock ES, Peremislov D, Gibney MA, Parvu V, Hirsch LJ. Safety and efficacy of insulin therapy delivered via a 4 mm pen needle in obese patients with diabetes. Mayo Clin Proc. 2015;90:329–38.CrossRefPubMed Bergenstal RM, Strock ES, Peremislov D, Gibney MA, Parvu V, Hirsch LJ. Safety and efficacy of insulin therapy delivered via a 4 mm pen needle in obese patients with diabetes. Mayo Clin Proc. 2015;90:329–38.CrossRefPubMed
22.
go back to reference De Coninck C, Frid A, Gaspar R, et al. Results and analysis of the 2008–2009 insulin injection technique questionnaire survey. J Diabetes. 2010;2:168–79.CrossRefPubMed De Coninck C, Frid A, Gaspar R, et al. Results and analysis of the 2008–2009 insulin injection technique questionnaire survey. J Diabetes. 2010;2:168–79.CrossRefPubMed
23.
go back to reference UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33. Lancet. 1998;352:837–53.CrossRef UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33. Lancet. 1998;352:837–53.CrossRef
24.
go back to reference Cukierman-Yaffe T, Gerstein HC, Williamson JD, et al. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care. 2009;32:221–6.CrossRefPubMedPubMedCentral Cukierman-Yaffe T, Gerstein HC, Williamson JD, et al. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care. 2009;32:221–6.CrossRefPubMedPubMedCentral
25.
go back to reference Pastors JG, Warshaw H, Daly A, Franz M, Kulkarni K. The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes Care. 2002;25:608–13.CrossRefPubMed Pastors JG, Warshaw H, Daly A, Franz M, Kulkarni K. The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes Care. 2002;25:608–13.CrossRefPubMed
Metadata
Title
A Randomized Controlled Trial to Assess the Impact of Proper Insulin Injection Technique Training on Glycemic Control
Authors
Inna V. Misnikova
Valeria A. Gubkina
Tatyana S. Lakeeva
Alexander V. Dreval
Publication date
01-12-2017
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 6/2017
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-017-0315-y

Other articles of this Issue 6/2017

Diabetes Therapy 6/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.